VivoSeq
Immunology

Systemic Lupus Erythematosus

278

Pipeline Programs↗

137

Active Trials↗

114

Companies Involved↗

Systemic Lupus Erythematosus is a highly competitive landscape with 278 programs across 114 companies. The most active players are Nanjing Legend Biotech Co., Shanghai Ming Ju Biotechnology Co., Ltd., Resolve Therapeutics. 26 therapies are approved with 40 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

88/100

Pipeline Velocity

65/100

Mech. Concentration

9/100

Completion Rate

76/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

N

Nanjing Legend Biotech Co.

2 programs

Phase 1S

Shanghai Ming Ju Biotechnology Co., Ltd.

1 program

Phase 1R

Resolve Therapeutics

1 program

Phase 1N

Nektar Therapeutics

1 program

Phase 1H

Hangzhou Sumgen Biotech Co., Ltd.

1 program

Phase 1C

China Immunotech (Beijing) Biotechnology Co., Ltd.

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical25

Duloxetine Hydrochloride

Eli Lilly

Hydroxychloroquine Sulfate

Novartis

Calcium

Eli Lilly

Dexamethasone Sodium Phosphate

Quince Therapeutics S.p.A.

Modafinil

Nuvo Research GmbH

Phase 195

Belimumab

Glaxo Dba Glaxosmithkline

Tocilizumab

Roche

PF-06835375

Pfizer

Methylprednisolone Sodium Succinate

Massachusetts Eye and Ear Infirmary

Filgrastim

Eastern Cooperative Oncology Group

Phase 292

Curcumin

Merck & Co.

Brentuximab Vedotin

Pfizer

Sulfasalazine

Pfizer

Iberdomide

Bristol-Myers Squibb

Daratumumab

Johnson & Johnson

Phase 340

Aldesleukin

Iovance Biotherapeutics, Inc.

Diphenhydramine

Parkedale

Ocrelizumab

Roche

Azathioprine

Legacy Health System

Medroxyprogesterone Acetate

Eli Lilly

Approved26

Hydroxychloroquine

Alnylam Pharmaceuticals

Clopidogrel

Sanofi

Mycophenolate Mofetil

Roche

Anifrolumab

AstraZeneca

Acetylcysteine

Arbor Pharmaceuticals, Inc.

Analysis

Modality Breakdown

75%

Small molecule

212 of 282 classified programs — the dominant modality here.

25%ALL OTHERSCell therapy3512%Monoclonal antibody259%Protein / enzyme83%Antibody–drug conjugate1<1%Vaccine1<1%

Small molecule leads; the ring shows all 282 classified programs, each share of the total. Modality classified for 98% of 329 pipeline programs.

Analysis

Trial Status

405

clinical trials

Completed180 · 44%
Recruiting81 · 20%
Terminated42 · 10%
Unknown status29 · 7%
Not yet recruiting29 · 7%
Active, not recruiting23 · 6%
Other21 · 5%

Clinical Trials

Trial Activity

405 trials

IM19 CAR-T Cell Therapy in Refractory Systemic Lupus Erythematosus (SLE)
Recruiting·PPeking University Third Hospital·N/A·NCT06513429·6 enrolled
A Study of LCAR-AIO in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus
Recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 1·NCT06653556·34 enrolled
Inaticabtagene Autoleucel Injection in the Treatment of Refractory Systemic Lupus Erythematosus-related Immune Thrombocytopenia
Recruiting·JJuventas Cell Therapy Ltd.·Phase 1·NCT06826430·12 enrolled
Clinical Study of Cizutamig in Systemic Lupus Erythematosus
Recruiting·CCandid Therapeutics·Phase 1·NCT07215663·47 enrolled
A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus
Recruiting·GGracell Biotechnologies (Shanghai) Co., Ltd.·Phase 1·NCT06530849·18 enrolled
Systemic Lupus Erythematosus and Accelerated Aging
Recruiting·UUniversity Hospital, Bordeaux·N/A·NCT05698173·75 enrolled
Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine
Recruiting·SState University of New York - Upstate Medical University·Phase 2·NCT00775476·290 enrolled
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
Recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 3·NCT07438496·600 enrolled
A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE) and Sjogren's Disease (SjD)
Recruiting·AbbVie logoAbbVie·Phase 1·NCT06977724·36 enrolled
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus
Recruiting·CCullinan Therapeutics Inc.·Phase 1·NCT06613360·24 enrolled
JY231 Injection for the Treatment of Active Systemic Lupus Erythematosus (SLE)
Recruiting·—·Phase 1/2·NCT06675422·20 enrolled
Study of YK012 in Moderate to Severe Systemic Lupus Erythematosus
Recruiting·EExcyte Biopharma Ltd·Phase 1/2·NCT07010835·189 enrolled
Clinical Study of A-319 in the Treatment of Active/Refractory Systemic Lupus Erythematosus
Recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 1·NCT06400537·25 enrolled
Efficacy and Safety of CD19 UCAR T Cells in Refractory Systemic Lupus Erythematosus
Recruiting·TThe Children's Hospital of Zhejiang University School of Medicine·Phase 1·NCT06691152·18 enrolled
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
Recruiting·AbbVie logoAbbVie·Phase 3·NCT05843643·1,000 enrolled
Page 1 of 27

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)